Reference number,Reference URL,First author,Title,Journal,Year,Country in which trial conducted,Continent in which trial conducted,Clinical trial phase (detail),Clinical trial phase (broad),Mechanism of action,ISCT compliance claimed,ISCT compliance demonstrated,Given indication,Indication class code,Indication class,Route of administration,Source of MSC,Stem or Stromal cell,Allogeneic or autologous,Donor sex,Donor Age,Stringency of characterisation,Osteogenic differentiation capacity,Adipogenic differentiation capacity,Chondrogenic differentiation capacity,Other differentiation capacity,Other differentiation capacity: Type,Co-occurence of differentiation capacity,Differentiation,"Number of characterisation attribute
 tests performed, value reported","Number of characterisation attribute
 tests performed, no value reported","Number of characterisation attribute
 tests performed, total",Viability qualifier,Viability value,Viability status,Viability test,CD73 qualifier,CD73 value,CD73 status,CD73 test,CD90 qualifier,CD90 value,CD90 status,CD90 test,CD105 qualifier,CD105 value,CD105 status,CD105 test,CD34 qualifier,CD34 value,CD34 status,CD34 test,CD45 qualifier,CD45 value,CD45 status,CD45 test,CD11b qualifier,CD11b value,CD11b status,CD11b test,CD14 qualifier,CD14 value,CD14 status,CD14 test,CD79a qualifier,CD79a value,CD79a status,CD79a test,CD19 qualifier,CD19 value,CD19 status,CD19 test,HLA-DR qualifier,HLA-DR value,HLA-DR status,HLA-DR test,CD3 qualifier,CD3 value,CD3 test,CD13 value,CD13 test,CD31 qualifer,CD31 value,CD31 test,CD133 qualifier,CD133 value,CD133 status,CD133 test,CD166 qualifier,CD166 value,CD166 status,CD166 test,CD29 qualifier,CD29 value,CD29 status,CD29 test,CD44 qualifier,CD44 value,CD44 status,CD44 test,CD146 value,CD146 test,CD271 value,CD271 test,STRO-1 value,STRO-1 test,MSCA-1 value,MSCA-1 test,SSEA-4 value,SSEA-4 test,Other markers noted
ref_number,ref_url,ref_first_author,ref_title,journal,year,country,continent,phase,phase_condensed,MOA,ISCT_claimed,ISCT_compliance,indication,sum_indication_code,sum_indication,route,source,stem_stromal,allo_auto,donor_sex,donor_age,test_results,O,A,C,other,other_type,differentiation_co,differentiation,marker_p_count,marker_m_count,marker_pm_count,viability_qualifier,viability_value,viability_status,viability_test,CD73_qualifier,CD73_value,CD73_status,CD73_test,CD90_qualifier,CD90_value,CD90_status,CD90_test,CD105_qualifier,CD105_value,CD105_status,CD105_test,CD34_qualifier,CD34_value,CD34_status,CD34_test,CD45_qualifier,CD45_value,CD45_status,CD45_test,CD11b_qualifier,CD11b_value,CD11b_status,CD11b_test,CD14_qualifier,CD14_value,CD14_status,CD14_test,CD79a_qualifier,CD79a_value,CD79a_status,CD79a_test,CD19_qualifier,CD19_value,CD19_status,CD19_test,HLA-DR_qualifier,HLA-DR_value,HLA-DR_status,HLA-DR_test,CD3_qualifier,CD3_value,CD3_test,CD13_value,CD13_test,CD31_qualifer,CD31_value,CD31_test,CD133_qualifier,CD133_value,CD133_status,CD133_test,CD166_qualifier,CD166_value,CD166_status,CD166_test,CD29_qualifier,CD29_value,CD29_status,CD29_test,CD44_qualifier,CD44_value,CD44_status,CD44_test,CD146_value,CD146_test,CD271_value,CD271_test,STRO-1_value,STRO-1_test,MSCA-1_value,MSCA-1_test,SSEA-4_value,SSEA-4_test,other_markers_noted
1,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.18-0053,Matas,Umbilical Cord?Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial,Stem Cells Translational Medicine,2018,Chile,South America,I/II,I,Paracrine,y,n,Osteoarthritis,MS,Musculoskeletal,Intraarticular,Umbilical cord,Stromal,Allogeneic,Not stated,Not stated,2. Average % reported,"Performed, value reported","Performed, value reported","Performed, value reported","Performed, value reported",thrombospondin expression,"Demonstrated (OAC, other)",Yes,8,0,8,greater than,80,release,p,minimum,95,release,p,minimum,95,release,p,minimum,95,release,p,maximum,2,release,p,maximum,2,release,p,NA,NA,NA,n,maximum,2,release,p,NA,NA,release,n,NA,NA,release,n,maximum,2,release,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898688/,Huang,"A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy",CELL TRANSPLANTATION,2018,China,Asia,II,II,Multiple,y,n,Cerebral palsy,CNS,Nervous system,Intravenous,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,11,0,11,greater than,90,measure,p,greater than,95,measure,p,greater than,95,measure,p,greater than,95,measure,p,less than,2,measure,p,less than,2,measure,p,NA,NA,NA,n,less than,2,measure,p,less than,2,measure,p,less than,2,measure,p,less than,2,measure,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,greater than,95,NA,p,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788872/,Keller,"Feasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction",Stem Cells Translational Medicine,2018,USA,North America,I,I,Immune,n,n/a (not claimed),Bronchiolitis obliterans syndrome,Resp,Respiratory,Intravenous,Bone marrow,Stem,Allogeneic,Male,Adult,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,"Performed, no value reported",(1) T-cell proliferation inhibition (2) Cytokine expression,Claimed (other),No,9,0,9,greater than,70,release,p,greater than,95,release,p,greater than,95,release,p,greater than,95,release,p,less than,5,release,p,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,NA,NA,not stated,n,less than,5,release,p,less than,5,release,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
4,https://www.hindawi.com/journals/sci/2018/6495018/,Petinati,Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells,Stem Cells International,2018,Russia,Asia,I/IIa,I,Immune,n,n/a (not claimed),Transplant (haematopoeitic stem cell),IM,Immune,Intraosseous,Bone marrow,Stromal,Allogeneic,Not stated,Adult,4. Stated as 'standard phenotype',"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
5,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0139,Wang,Autologous Mesenchymal Stem Cell and Islet Co-transplantion: safety and efficacy,Stem Cells Translational Medicine,2018,USA,North America,I,I,Paracrine,n,n/a (not claimed),Transplant (islet cell),IM,Immune,Intravenous,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,8,0,8,greater than,70,release,p,greater than,95,release,p,greater than,95,release,p,greater than,95,release,p,NA,NA,NA,n,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,NA,NA,NA,n,NA,NA,NA,n,less than,5,release,p,NA,NA,n,NA,n,less than,5,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
6,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0041,Milczarek,Multiple Autologous Bone Marrow?Derived CD271+Mesenchymal Stem Cell Transplantation Overcomes Drug?Resistant Epilepsy in Children,Stem Cells Translational Medicine,2018,Poland,Europe,I,I,Paracrine,n,n/a (not claimed),Epilepsy,CNS,Nervous system,Intrathecal,Bone marrow,Stem,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,5,0,5,NA,NA,NA,n,greater than,95,measure,p,greater than,95,measure,p,greater than,95,measure,p,NA,NA,NA,n,less than,2,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,less than,2,p,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
7,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5702514/,Shi,A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection,Stem Cells Translational Medicine,2017,China,Asia,II,II,Immune,n,n/a (not claimed),Transplant (liver),IM,Immune,Intravenous,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,"Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Not mentioned,Demonstrated (OA),Yes,1,8,9,greater than,80,measure,p,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,X,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
8,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0040,Kastrup,Cryopreserved Off-the-Shelf Allogeneic AdiposeDerived Stromal Cells for Therapy in Patients with Ischemic Heart Disease and Heart Failure—A Safety Study,Stem Cells Translational Medicine,2017,Denmark,Europe,I,I,Not stated,y,n,Heart failure,CVS,Cardiovascular,Intracardiac,Adipose,Stromal,Allogeneic,Female,Adult,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,6,0,6,greater than,80,release,p,greater than,80,release,p,greater than,80,release,p,greater than,80,release,p,NA,NA,NA,n,less than,3,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,less than,5,release,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
9,https://journals.lww.com/transplantjournal/fulltext/2017/08000/Intervertebral_Disc_Repair_by_Allogeneic.38.aspx#pdf-link,Noriega,Intervertebral Disc Repair by Allogeneic Mesenchymal Bone Marrow Cells: A Randomized Controlled Trial,TRANSPLANTATION,2017,Spain,Europe,I/IIa,I,Paracrine,n,n/a (not claimed),Intervertebral disc repair,MS,Musculoskeletal,Local injection,Bone marrow,Stromal,Allogeneic,Not stated,Adult,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,0,1,minimum,97,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
10,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.16-0227,Pang,Allogeneic Bone?Marrow?Derived Mesenchymal stromal Cells Expanded in vitro for Treatment of Aplastic Anemia: A Multicenter Phase II Trial,Stem Cells Translational Medicine,2017,China,Asia,II,II,Immune,y,n,Aplastic anemia,Haem,Haematology,Intravenous,Bone marrow,Stromal,Allogeneic,Both,Adult,2. Average % reported,"Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Not mentioned,Demonstrated (OA),Yes,3,3,6,NA,NA,NA,n,greater than,92,measure,p,greater than,92,measure,p,greater than,92,NA,p,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
11,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.16-0372,Chambers,Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First?in?Man Study,Stem Cells Translational Medicine,2017,Australia,Australia,I,I,Immune,n,n/a (not claimed),Chronic Lung Allograft Dysfunction ,IM,Immune,Intravenous,Bone marrow,Stromal,Allogeneic,Both,Adult,4. Stated as 'standard phenotype',"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,1,4,5,greater than,70,release,p,NA,+,release,m,NA,+,release,m,NA,+,release,m,NA,NA,NA,n,NA,X,release,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
12,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.16-0199,Whitehouse,Repair of Torn Avascular Meniscal Cartilage Using Undifferentiated Autologous Mesenchymal Stem Cells: From In Vitro Optimization to a First?in?Human Study,Stem Cells Translational Medicine,2017,UK,Europe,I/IIa,I,Paracrine,n,n/a (not claimed),Meniscus repair,MS,Musculoskeletal,Implant,Bone marrow,Stem,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,5,0,5,greater than,90,measure,p,NA,NA,NA,n,greater than,80,release,p,greater than,80,release,p,less than,10,release,p,less than,10,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
13,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.5966/sctm.2016-0237,Gupta,"Administration of Adult Human Bone Marrow?Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger’s Disease: Phase II Study Report Suggests Clinical Efficacy",Stem Cells Translational Medicine,2017,India,Asia,II,II,Paracrine,n,n/a (not claimed),Critical limb ischaemia,CVS,Cardiovascular,Intramuscular,Bone marrow,Stromal,Allogeneic,Not stated,Adult,2. Average % reported,"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,11,0,11,greater than,85,release,p,greater than,80,release,p,greater than,80,release,p,greater than,80,release,p,less than,5,release,p,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,less than,5,release,p,NA,NA,n,NA,n,NA,NA,n,less than,5,release,p,greater than,80,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
14,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.16-0315,de Oliveira,Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial,Stem Cells Translational Medicine,2017,Brazil,South America,I,I,Paracrine,n,n/a (not claimed),Pulmonary emphysema,Resp,Respiratory,Topical,Bone marrow,Stromal,Allogeneic,Not stated,Adult,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,11,0,11,NA,I,NA,p,NA,I,NA,p,NA,I,NA,p,NA,I,NA,p,NA,I,NA,p,NA,I,NA,p,NA,NA,NA,n,NA,I,NA,p,NA,NA,NA,n,NA,I,NA,p,NA,I,NA,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,I,NA,p,NA,I,NA,p,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
15,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442809/,Park,Cartilage Regeneration in Osteoarthritic Patients by a Composite of Allogeneic Umbilical Cord Blood?Derived Mesenchymal Stem Cells and Hyaluronate Hydrogel: Results from a Clinical Trial for Safety and Proof?of?Concept with 7 Years of Extended Follow?Up,Stem Cells Translational Medicine,2017,Korea (Republic of),Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Osteoarthritis,MS,Musculoskeletal,Intraarticular,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,4. Stated as 'standard phenotype',Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
16,https://www.hindawi.com/journals/sci/2017/5237063/,Qayyam,Adipose-Derived Stromal Cells for Treatment of Patients with Chronic Ischemic Heart Disease (MyStromalCell Trial): A Randomized Placebo-Controlled Study,Stem Cells Translational Medicine,2017,Denmark,Europe,II,II,Paracrine,y,n,Angina,CVS,Cardiovascular,Intracardiac,Adipose,Stromal,Autologous,Not stated,Not stated,4. Stated as 'standard phenotype',Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
17,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.18-0183,Chahal,Bone Marrow Mesenchymal Stromal Cells in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation,Stem Cells Translational Medicine,2019,Canada,North America,I/IIa,I,Paracrine,y,n,Osteoarthritis,MS,Musculoskeletal,Intraarticular,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,9,0,9,minimum,70,release,p,minimum,95,release,p,minimum,95,release,p,minimum,95,release,p,maximum,2,release,p,maximum,2,release,p,NA,NA,NA,n,maximum,2,release,p,NA,NA,NA,n,maximum,2,release,p,maximum,2,release,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
18,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.18-0122,Lee,"Intra?Articular Injection of Autologous Adipose Tissue?Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis: A Phase IIb, Randomized, Placebo?Controlled Clinical Trial",Stem Cells Translational Medicine,2019,Korea (Republic of),Asia,IIb,II,Paracrine,n,n/a (not claimed),Osteoarthritis,MS,Musculoskeletal,Intraarticular,Adipose,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,5,6,average,92.8,measure,p,NA,d,NA,m,NA,d,NA,m,NA,NA,NA,n,NA,d,NA,m,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,d,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
19,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.18-0230,Schweizer,A Phase I Study to Assess the Safety and Cancer?Homing Ability of Allogeneic Bone Marrow?Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer,Stem Cells Translational Medicine,2019,USA,North America,I,I,Paracrine,n,n/a (not claimed),Tumour homing,TH,Tumour homing,Intravenous,Bone marrow,Stem,Allogeneic,Male,Adult,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
20,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301165/,Barczewska,Safety of intrathecal injection of Wharton’s jelly-derived mesenchymal stem cells in amyotrophic lateral sclerosis therapy,Neural Regeneration Research,2019,Poland,Europe,I,I,Paracrine,n,n/a (not claimed),Amyotrophic lateral sclerosis,CNS,Nervous system,Intrathecal,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
21,https://www.ncbi.nlm.nih.gov/pubmed/28684893,Bhasin,Safety and Feasibility of Autologous Mesenchymal Stem Cell Transplantation in Chronic Stroke in Indian patients. A four-year follow up,J Stem Cells & Regen Med,2017,India,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Stroke (multiple aetiologies),CeV,Cerebrovascular,Intravenous,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,4,1,5,average,98,measure,p,average,57.1,measure,p,average,61,measure,p,average,40,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
22,https://journals.sagepub.com/doi/full/10.3727/096368917X695038,Zhao,Clinical Study of NeuroRegen Scaffold Combined With Human Mesenchymal Stem Cells for the Repair of Chronic Complete Spinal Cord Injury,CELL TRANSPLANTATION,2017,China,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Implant,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,7,7,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
23,https://stemcellsjournals.onlinelibrary.wiley.com/doi/epdf/10.5966/sctm.2015-0356,Garcia-Arranz,Treatment of Crohn’s-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I–IIa Clinical Trial,Stem Cells Translational Medicine,2016,Spain,Europe,I/IIa,I,Not stated,y,n/a (not claimed),Perianal fistula (Crohn's),GU,Genito-urinary,Local injection,Adipose,Stem,Allogeneic,Not stated,Not stated,4. Stated as 'standard phenotype',Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
24,https://online.boneandjoint.org.uk/doi/full/10.1302/2046-3758.57.2000587,Ismail,Mesenchymal stem cell implantation in atrophic nonunion of the long bones,Bone & Joint Research,2016,Indonesia,Asia,I/IIa,I,Not stated,n,n/a (not claimed),Bone non-union,MS,Musculoskeletal,Implant,Bone marrow,Stem,Autologous,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,6,7,average,89.97,measure,p,NA,d,NA,m,NA,NA,NA,n,NA,d,NA,m,NA,d,NA,m,NA,d,NA,m,NA,NA,NA,n,NA,d,NA,m,NA,NA,NA,n,NA,d,NA,n,NA,d,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
25,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.5966/sctm.2015-0245,Pers,Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a Phase I dose-escalation trial,Stem Cells Translational Medicine,2016,France & Germany,Europe,I,I,Paracrine,n,n/a (not claimed),Osteoarthritis,MS,Musculoskeletal,Intraarticular,Adipose,Stromal,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,7,0,7,greater than,90,release,p,greater than,90,release,p,greater than,90,release,p,greater than,80,release,p,less than,10,release,p,less than,2,release,p,NA,NA,NA,n,less than,2,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
26,https://www.hindawi.com/journals/sci/2016/6205910/,Baba,Phase I/II Trial of Autologous Bone Marrow Stem Cell Transplantation with a Three-Dimensional Woven-Fabric Scaffold for Periodontitis,Stem Cells International,2016,Japan,Asia,I/IIa,I,Differentiation,n,n/a (not claimed),Periodontitis,DG,Digestive tract,Implant,Bone marrow,Stem,Autologous,Not stated,Not stated,5. No characterisation discussed,"Performed, value reported",Not mentioned,Not mentioned,"Performed, value reported",osteogenic capacity of MSC in study confirmed in vitro,Demonstrated (O),Yes,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
27,https://www.hindawi.com/journals/sci/2016/1641402/,Erbey,Mesenchymal Stem Cell Treatment for Steroid Refractory Graft-versus-Host Disease in Children: A Pilot and First Study from Turkey,Stem Cells International,2016,Turkey,Asia,I/IIa,I,Immune,n,n/a (not claimed),Graft vs host disease,IM,Immune,Intravenous,Bone marrow,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,7,8,minimum,90,release,p,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
28,https://journals.lww.com/transplantjournal/fulltext/2015/08000/Treatment_of_Knee_Osteoarthritis_With_Allogeneic.27.aspx,Vega,Treatment of Knee Osteoarthritis With Allogeneic Bone Marrow Mesenchymal Stem Cells: A Randomized Controlled Trial,TRANSPLANTATION,2015,Spain,Europe,I/IIa,I,Not stated,y,n,Osteoarthritis,MS,Musculoskeletal,Intraarticular,Bone marrow,Stem,Allogeneic,Not stated,Not stated,4. Stated as 'standard phenotype',Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
29,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.5966/sctm.2014-0212,Oh,Phase I Trial of Repeated Intrathecal Autologous Bone Marrow?Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis,Stem Cells Translational Medicine,2015,Korea (Republic of),Asia,I,I,Paracrine,n,n/a (not claimed),Amyotrophic lateral sclerosis,CNS,Nervous system,Intrathecal,Bone marrow,Stromal,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,6,0,6,NA,NA,NA,n,NA,I,measure,p,NA,NA,NA,n,NA,I,measure,p,NA,I,measure,p,NA,I,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,I,NA,p,NA,I,NA,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
30,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495125/,Musialek,Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf ‘unlimited’ therapeutic agent: results from the Acute Myocardial Infarction First-in-Man Study,Postepy w Kardiologii Interwencyjnej,2015,Poland,Europe,I,I,Not stated,n,n/a (not claimed),Myocardial infarction,CVS,Cardiovascular,Intracoronary,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,3,1,4,NA,NA,NA,n,minimum,95,measure,p,minimum,95,measure,p,greater than,95,measure,p,NA,NA,NA,n,NA,X,measure,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
31,https://journals.sagepub.com/doi/full/10.3727/096368913X667727,Wang,Effects and Safety of Allogenic Mesenchymal Stem Cell Intravenous Infusion in Active Ankylosing Spondylitis Patients who Failed NSAIDs: A 20-Week Clinical Trial,CELL TRANSPLANTATION,2014,China,Asia,II,II,Paracrine,y,n,Ankylosing spondylitis,MS,Musculoskeletal,Intravenous,Bone marrow,Stem,Allogeneic,Male,Adult,4. Stated as 'standard phenotype',"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,0,6,6,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
32,https://journals.sagepub.com/doi/full/10.3727/096368912X661319,Liu,Improvement in Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation upon Administration of Mesenchymal Stem Cells from Third-Party Donors: A Pilot Prospective Study,CELL TRANSPLANTATION,2014,China,Asia,I/IIa,I,Not stated,n,n/a (not claimed),Transplant (haematopoeitic stem cell),IM,Immune,Intravenous,Bone marrow,Stem,Allogeneic,Both,Adult,2. Average % reported,"Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Not mentioned,Demonstrated (OA),Yes,8,1,9,NA,NA,NA,n,NA,99.68,measure,p,NA,97.56,measure,p,NA,99.3,measure,p,NA,0.08,measure,p,NA,0.09,measure,p,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,95.54,measure,p,NA,99.57,measure,p,NA,99.75,NA,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
33,https://www.sciencedirect.com/science/article/pii/S0006899313011190?via%3Dihub,Dai,Transplantation of autologous bone marrow mesenchymal stem cells in the treatment of complete and chronic cervical spinal cord injury,BRAIN RESEARCH,2013,China,Asia,II,II,Multiple,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Local injection,Bone marrow,Stem,Autologous,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
34,https://link.springer.com/article/10.1186/s12967-016-0998-2,Lamo-Espinosa,Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: multicenter randomized controlled clinical trial (phase I/II),Journal of Translational Medicine,2016,Spain,Europe,I/IIa,I,Paracrine,y,n,Osteoarthritis,MS,Musculoskeletal,Intraarticular,Bone marrow,Stem,Autologous,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,5,5,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,NA,NA,n,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
35,https://journals.lww.com/transplantjournal/fulltext/2013/06270/Treatment_of_Knee_Osteoarthritis_With_Autologous.17.aspx,Orozco,Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells: A Pilot Study,TRANSPLANTATION,2013,Spain,Europe,I/IIa,I,Multiple,y,n,Osteoarthritis,MS,Musculoskeletal,Intraarticular,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,6,7,greater than,85,measure,p,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,"KDR (VEGFR2) +, CD106+"
36,https://journals.lww.com/transplantjournal/fulltext/2013/03150/Cotransplantation_of_Umbilical_Cord_Derived.20.aspx,Wu,Cotransplantation of Umbilical Cord–Derived Mesenchymal Stem CellsPromote Hematopoietic Engraftment in Cord Blood Transplantation: A Pilot Study,TRANSPLANTATION,2013,Taiwan,Asia,I/IIa,I,Immune,n,n/a (not claimed),Transplant (haematopoeitic stem cell),IM,Immune,Intravenous,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,3. Tests done but % not reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,0,11,11,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,+,m,NA,X,m,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
37,https://journals.sagepub.com/doi/full/10.3727/096368912X639017?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,Scuderi,Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis.,CELL TRANSPLANTATION,2013,Italy,Europe,I/IIa,I,Immune,n,n/a (not claimed),Systemic sclerosis,IM,Immune,Subcutaneous,Adipose,Stromal,Autologous,Not stated,Not stated,2. Average % reported,"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,9,1,10,NA,d,NA,m,average,99.2,measure,p,average,99.64,measure,p,average,98.23,measure,p,average,6.47,measure,p,average,12.52,measure,p,NA,NA,NA,n,average,23.73,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,average,84.16,measure,p,NA,93.57,measure,p,NA,95.21,NA,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
38,https://www.researchgate.net/profile/Jens_Kastrup/publication/51044795_Mesenchymal_stromal_cell_derived_endothelial_progenitor_treatment_in_patients_with_refractory_angina/links/00b7d5188dcf5a06cb000000.pdf,Friis,Mesenchymal stromal cell derived endothelial progenitor cell treatment in patients with severe refractory angina. Scand. Cardiovasc. J. 45:161–168; 2011,SCANDINAVIAN CARDIOVASCULAR JOURNAL,2011,Denmark,Europe,I/IIa,I,Not stated,n,n/a (not claimed),Angina,CVS,Cardiovascular,Intracardiac,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,6,0,6,NA,NA,NA,n,NA,92.4,NA,p,NA,92.5,NA,p,NA,91.8,NA,p,NA,4,NA,p,NA,1,NA,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,92.9,p,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
39,https://journals.sagepub.com/doi/full/10.3727/096368912X656045?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,Cho,Autologous Adipose Tissue-Derived Stem Cells for the Treatment of Crohn's Fistula: A Phase I Clinical Study,CELL TRANSPLANTATION,2013,Korea (Republic of),Asia,I,I,Multiple,n,n/a (not claimed),Perianal fistula (Crohn's),GU,Genito-urinary,Local injection,Adipose,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,3,5,8,greater than,90,measure,p,NA,NA,NA,n,greater than,90,measure,p,NA,NA,NA,n,NA,X,NA,m,less than,10,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,+,m,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,n,NA,n,X,m,NA,n,NA,n,CD10+
40,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253492/,Kuzmina,Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study,Stem Cells International,2012,Russia,Asia,II,II,Immune,n,n/a (not claimed),Graft vs host disease,IM,Immune,Intravenous,Bone marrow,Multipotent Stromal,Allogeneic,Both,Adult,2. Average % reported,"Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Not mentioned,Claimed (OA),Yes,9,0,9,average,95.3,measure,p,average,98.1,measure,p,average,98,measure,p,average,98.6,measure,p,NA,0,measure,p,average,4.5,measure,p,NA,NA,NA,n,average,2,measure,p,NA,NA,NA,n,NA,NA,NA,n,average,3.7,measure,p,NA,NA,n,NA,n,NA,2.5,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,"CD59 average 98.8%, FSP average 97%"
41,https://journals.lww.com/transplantjournal/fulltext/2011/10150/Intervertebral_Disc_Repair_by_Autologous.20.aspx,Orozco,Intervertebral Disc Repair by Autologous Mesenchymal Bone Marrow Cells: A Pilot Study,TRANSPLANTATION,2011,Spain,Europe,I/IIa,I,Multiple,y,n,Intervertebral disc repair,MS,Musculoskeletal,Local injection,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,1,7,8,average,87,measure,p,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,NA,NA,n,NA,NA,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,"KDR (VEGFR2) +, CD106+"
42,https://journals.lww.com/transplantjournal/fulltext/2011/06270/Effective_Treatment_of_Severe_Steroid_Resistant.19.aspx#pdf-link,Wu,Effective Treatment of Severe Steroid-Resistant Acute Graft-Versus-Host Disease With Umbilical Cord-Derived Mesenchymal Stem Cells,STEM CELLS,2011,Taiwan,Asia,I,I,Immune,n,n/a (not claimed),Graft vs host disease,IM,Immune,Intravenous,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,3. Tests done but % not reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,0,11,11,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,+,m,NA,X,m,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
43,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172930/,Cheng H,Clinical observation of umbilical cord mesenchymal stem cell transplantation in treatment for sequelae of thoracolumbar spinal cord injury,Journal of Translational Medicine,2014,China,Asia,II,II,Paracrine,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Local injection,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,8,0,8,NA,NA,NA,n,greater than,95,measure,p,greater than,95,measure,p,greater than,95,measure,p,less than,5,measure,p,less than,5,measure,p,less than,5,measure,p,NA,NA,NA,n,NA,NA,NA,n,less than,5,measure,p,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,95,NA,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
44,https://www.sciencedirect.com/science/article/pii/S1465324914008093?via%3Dihub,Chullikana,"Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction",CYTOTHERAPY,2015,India,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Myocardial infarction,CVS,Cardiovascular,Intravenous,Bone marrow,Stromal,Allogeneic,Not stated,Adult,1. % by batch reported,"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,11,0,11,minimum,85,release,p,greater than,85,release,p,greater than,85,release,p,greater than,85,release,p,less than,5,release,p,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,NA,NA,NA,n,less than,5,release,p,less than,5,release,p,NA,NA,n,NA,n,NA,NA,n,less than,5,release,p,greater than,85,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
45,https://link.springer.com/article/10.1007%2Fs00384-012-1581-9#Sec11,de la Portilla,Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/IIa clinical trial,INTERNATIONAL JOURNAL OF COLORECTAL DISEASE,2013,Spain,Europe,I/IIa,I,Immune,n,n/a (not claimed),Perianal fistula (Crohn's),GU,Genito-urinary,Local injection,Adipose,Stem,Allogeneic,Not stated,Adult,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,"Performed, no value reported",Claimed (other),No,0,1,1,NA,d,measure,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
46,https://www.sciencedirect.com/science/article/pii/S0167527313007481?via%3Dihub,Gao L,A critical challenge: Dosage-related efficacy and acute complication intracoronary injection of autologous bone marrow mesenchymal stem cells in acute myocardial infarction,INTERNATIONAL JOURNAL OF CARDIOLOGY,2013,China,Asia,II,II,Not stated,y,n,Myocardial infarction,CeV,Cerebrovascular,Intracoronary,Bone marrow,Stem,Autologous,Not stated,Not stated,1. % by batch reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,8,0,8,average,91.4,measure,p,average,93.7,measure,p,average,92.6,measure,p,average,94.3,measure,p,average,2.5,measure,p,average,1.2,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,average,2.1,measure,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,average,91.2,measure,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
47,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499169/,Gao L,"Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial",BMC Medicine,2015,China,Asia,IIb,II,Multiple,n,n/a (not claimed),Myocardial infarction,CVS,Cardiovascular,Intracoronary,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,10,0,10,minimum,85,measure,p,minimum,95,measure,p,minimum,95,measure,p,minimum,95,measure,p,maximum,2,measure,p,maximum,2,measure,p,NA,NA,NA,n,maximum,2,measure,p,maximum,2,measure,p,NA,NA,NA,n,maximum,2,measure,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,minimum,95,measure,p,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
48,https://journals.sagepub.com/doi/full/10.3727/096368912X636830?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed,Haack-Sorensen,Direct Intramyocardial Mesenchymal Stromal Cell Injections in Patients With Severe Refractory Angina: One-Year Follow-Up,CELL TRANSPLANTATION,2013,Denmark,Europe,IIa,II,Not stated,n,n/a (not claimed),Angina,CVS,Cardiovascular,Intracardiac,Bone marrow,Stromal,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,6,0,6,NA,NA,NA,n,NA,92.4,measure,p,NA,92.5,measure,p,NA,91.8,measure,p,NA,4,measure,p,NA,1,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,92.9,p,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
49,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102237/,Honmou O,Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke,BRAIN RESEARCH,2011,Japan,Asia,I,I,Multiple,n,n/a (not claimed),Stroke (ischaemic),CeV,Cerebrovascular,Intravenous,Bone marrow,Stem,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,3,4,greater than,95.2,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,d,NA,m,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
50,https://www.sciencedirect.com/science/article/pii/S0735109711048741?via%3Dihub,Houtgraaf,First Experience in Humans Using Adipose Tissue-Derived Regenerative Cells in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction,J American College of Cardiology,2011,Netherlands,Europe,I/IIa,I,Paracrine,n,n/a (not claimed),Myocardial infarction,CVS,Cardiovascular,Intracoronary,Adipose,Regenerative,Autologous,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
51,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5137573/,Hur,Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial,JOURNAL OF SPINAL CORD MEDICINE,2016,Korea (Republic of),Asia,I,I,Not stated,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Adipose,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,3,0,3,minimum,80,release,p,NA,NA,NA,n,minimum,80,release,p,NA,NA,NA,n,NA,NA,NA,n,less than,1,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
52,http://www.eurekaselect.com/105867/article,Jin JL,Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellla Ataxia,CURRENT NEUROVASCULAR RESEARCH,2013,China,Asia,I/IIa,I,Not stated,n,n/a (not claimed),Spinocerebellar ataxia,CNS,Nervous system,Intrathecal,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,8,0,8,greater than,95,measure,p,NA,95.3,measure,p,NA,98.2,measure,p,NA,99.1,measure,p,NA,0.4,measure,p,NA,0.4,measure,p,NA,NA,NA,n,NA,0.3,measure,p,NA,0.2,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
53,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.1634,Jo,Intra-Articular Injection of Mesenchymal Stem Cells for the Treatment of Osteoarthritis of the Knee: A Proof-of-Concept Clinical Trial,STEM CELLS,2014,Korea (Republic of),Asia,II,II,Multiple,n,n/a (not claimed),Osteoarthritis,MS,Musculoskeletal,Intraarticular,Adipose,Stem,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,4,2,6,NA,d,NA,m,NA,I,NA,m,NA,I,NA,p,NA,NA,NA,n,NA,I,NA,p,NA,I,NA,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,I,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
54,https://www.sciencedirect.com/science/article/pii/S0303846712000868?via%3Dihub,Karamouzian,Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantaion in subacute spinal cord injured patients,CLINICAL NEUROLOGY AND NEUROSURGERY,2012,Iran,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Bone marrow,Stem,Autologous,Not stated,Not stated,5. No characterisation discussed,"Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Not mentioned,Demonstrated (OA),Yes,0,1,1,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
55,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4104798/,Karantalis,"Autologous Mesenchymal Stem Cells Produce Concordant Improvements in Regional Function, Tissue Perfusion and Fibrotic Burden when Administered to Patients Undergoing Coronary Artery Bypass Grafting - The PROMETHEUS Trial",CIRCULATION RESEARCH,2014,USA,North America,IIa,II,Not stated,n,n/a (not claimed),Coronary artery bypass graft,CVS,Cardiovascular,Intracardiac,Bone marrow,Stem,Autologous,Not stated,Not stated,1. % by batch reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,2,1,3,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,I,NA,p,NA,NA,NA,n,NA,I,NA,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
56,https://www.ncbi.nlm.nih.gov/pubmed/24966156,Kim HY,Biological Markers of Mesenchymal Stromal Cells as Predictors of Response to Autologous Stem Cell Transplantation in Patients with Amyotropic Lateral Sclerosis: An Investigator-initiated Trial and In-Vivo Study,STEM CELLS,2014,Korea (Republic of),Asia,II,II,Paracrine,n,n/a (not claimed),Amyotrophic lateral sclerosis,CNS,Nervous system,Intrathecal,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,6,7,greater than,80,measure,p,NA,+,NA,m,NA,NA,NA,n,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
57,https://journals.sagepub.com/doi/abs/10.1177/1545968310369801,Kishk,Case Control Series of Intrathecal Autologous Bone Marrow Mesenchmal Stem Cell Therapy for Chronic Spinal Cord Injury,NEUROREHABILITATION AND NEURAL REPAIR,2010,Egypt,Africa,II,II,Not stated,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Bone marrow,Stem,Autologous,Not stated,Not stated,3. Tests done but % not reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,0,3,3,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
58,https://www.sciencedirect.com/science/article/pii/S1465324917306229?via%3Dihub,Larocca,Image-guided percutaneous intralesional administration of mesenchymal stromal cells in subjects with chronic complete sinal cord injury: a pilot study,CYTOTHERAPY,2017,Brazil,South America,I/IIa,I,Not stated,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Local injection,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,"Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Not mentioned,Claimed (OA),Yes,6,0,6,NA,NA,NA,n,average,99.8,measure,p,average,99.9,measure,p,average,98.2,measure,p,NA,NA,NA,n,average,0.3,measure,p,average,0.1,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,average,90.7,measure,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
59,https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/stem.430,Lee JS,A Long-Term Follow-Up Study of Intravenous Autologous Mesenchymal Stem Cell Tansplantation in Patients with Ischemic Stroke,STEM CELLS,2010,Korea (Republic of),Asia,II,II,Paracrine,n,n/a (not claimed),Stroke (ischaemic),CeV,Cerebrovascular,Intravenous,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,2,0,2,greater than,95,measure,p,NA,NA,NA,n,NA,NA,NA,n,greater than,90,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
60,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5324263/,Liu X,Comparative analysis of curative effect of bone marrrow mesenchymal stem cell and bone marrow mononuclear cell transplantaion for spastic cerebral palsy,Journal of Translational Medicine,2017,China,Asia,III,III,Paracrine,n,n/a (not claimed),Cerebral palsy,CNS,Nervous system,Intrathecal,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,8,0,8,NA,NA,NA,n,minimum,95,measure,p,NA,NA,NA,n,minimum,95,measure,p,maximum,2,measure,p,maximum,2,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,maximum,2,measure,p,NA,NA,n,NA,n,NA,2,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,minimum,95,measure,p,2,p,NA,n,NA,n,NA,n,NA,n,NA
61,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250058/,Llufriu,Randomized Placebo-Controlled Phase II Trial of Atuologous Mesenchymal Stem Cells in Multiple Sclerosis,PLoS One,2014,Spain,Europe,II,II,Immune,n,n/a (not claimed),Multiple sclerosis,CNS,Nervous system,Intravenous,Bone marrow,Stem,Autologous,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,5,5,NA,NA,NA,n,NA,+,NA,m,NA,+,NA,m,NA,NA,NA,n,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,+,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,NA
62,https://pubmed.ncbi.nlm.nih.gov/25926562/,Mathiasen,Bone marrow-derived mesenchymal stromal cell treatment in patiens with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial),EUROPEAN HEART JOURNAL,2015,Denmark,Europe,II,II,Paracrine,y,n,Heart failure,CVS,Cardiovascular,Intracardiac,Bone marrow,Stromal,Autologous,Not stated,Not stated,4. Stated as 'standard phenotype',Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,0,1,average,90,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
63,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445989/,Mendonca,Safety and neurological assessments after autologous transplantation of bone marrow mesenchymal stem cells in subjects with chronic spinal cord injury,Stem Cell Research & Therapy,2014,Brazil,South America,I,I,Not stated,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Local injection,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,7,3,10,NA,NA,NA,n,average,97.5,measure,p,average,96.6,measure,p,average,97.4,measure,p,average,2.3,measure,p,average,2,measure,p,NA,NA,NA,n,average,2.3,measure,p,average,2.4,measure,p,NA,d,NA,m,NA,NA,NA,n,NA,NA,n,NA,n,NA,d,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,n,NA,n,NA,n,NA,n,NA,n,CD117
64,https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.117.310712,Bartolucci,Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure,CIRCULATION RESEARCH,2017,Chile,South America,I/IIa,I,Paracrine,y,n,Heart failure,CVS,Cardiovascular,Intravenous,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,"Performed, value reported","Performed, value reported","Performed, value reported",Not mentioned,Not mentioned,Demonstrated (OAC),Yes,11,0,11,greater than,80,release,p,minimum,95,release,p,minimum,95,release,p,minimum,95,release,p,maximum,2,release,p,maximum,2,release,p,NA,NA,NA,n,maximum,2,release,p,NA,NA,NA,n,NA,NA,NA,n,maximum,2,release,p,NA,NA,n,NA,n,NA,0,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,98,NA,p,99.8,p,NA,n,NA,n,NA,n,NA,n,CD49a
65,https://pubmed.ncbi.nlm.nih.gov/27477896/,Panes,"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial",LANCET,2016,Multiple,Europe,III,III,Immune,n,n/a (not claimed),Perianal fistula (Crohn's),GU,Genito-urinary,Local injection,Adipose,Stem,Allogeneic,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
66,https://pubmed.ncbi.nlm.nih.gov/26603576/,Park KJ,Allogeneic adipose-derived stem cells for the treatment of perianal fistula in Crohn’s disease: a pilot clinical trial,The Association of Coloproctology of Great Britain and Ireland,2015,Korea (Republic of),Asia,I/IIa,I,Immune,n,n/a (not claimed),Perianal fistula (Crohn's),GU,Genito-urinary,Local injection,Adipose,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,0,1,minimum,80,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
67,https://pubmed.ncbi.nlm.nih.gov/26148930/,Perin,A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients with Ischemic or Nonischemic Heart Failure,CIRCULATION RESEARCH,2015,USA,North America,II,II,Paracrine,n,n/a (not claimed),Heart failure,CVS,Cardiovascular,Intracardiac,Bone marrow,Stem,Allogeneic,Male,Adult,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,4,5,minimum,70,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,d,NA,m,NA,NA,n,NA,n,NA,d,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,d,m,NA,n,NA,n,"STRO-1, STRO-3, CC9"
68,https://pubmed.ncbi.nlm.nih.gov/26751635/,Petrou,Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurorophic Factor Transplantation in Patients with Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical trials,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,2016,Israel,Asia,I/IIa,I,Multiple,n,n/a (not claimed),Amyotrophic lateral sclerosis,CNS,Nervous system,Intrathecal,Bone marrow,Stem,Autologous,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,"Performed, value reported","NTF secretion (BDNF, GDNF)",Claimed (other),No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
69,https://pubmed.ncbi.nlm.nih.gov/25333752/,Qiao L,A Two-Year Follow-Up Study of Cotransplantation Wih Neural Stem/Progenitor Cells and Mesenchymal Stromal Cells in Ischemic Stroke Patients,CELL TRANSPLANTATION,2014,China,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Stroke (ischaemic),CeV,Cerebrovascular,Intravenous,Umbilical cord,Stromal,Allogeneic,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
70,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790917/,Rodrigo,Intramyocardial Injection of Autologous Bone Marrow-Derived Ex-Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5 Years of Follow-up,Journal of Cardiovascular Translational Research,2013,Netherlands,Europe,I/IIa,I,Paracrine,y,n,Myocardial infarction,CeV,Cerebrovascular,Intracardiac,Bone marrow,Stem,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,7,8,average,93,measure,p,NA,+,NA,m,NA,+,NA,m,NA,+,NA,m,NA,X,NA,m,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,X,NA,m,NA,NA,n,NA,n,NA,X,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
71,https://www.sciencedirect.com/science/article/pii/S1465324916000153,Satti,"Autologous mesenchymal stromal cell transplantation for spinal cord injury: A Phase I pilot study
",CYTOTHERAPY,2016,Pakistan,Asia,I,I,Not stated,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported",Not mentioned,Not mentioned,Claimed (OAC),Yes,5,1,6,NA,d,NA,m,greater than,97,measure,p,greater than,97,measure,p,greater than,97,measure,p,less than,3,measure,p,less than,3,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
72,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123559/,Staff,Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS,NEUROLOGY,2016,USA,North America,I,I,Paracrine,n,n/a (not claimed),Amyotrophic lateral sclerosis,CNS,Nervous system,Intrathecal,Adipose,Stromal,Autologous,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
73,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828512/,Steinberg,Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase1/2a Study,STROKE,2016,USA,North America,I/IIa,I,Paracrine,n,n/a (not claimed),Stroke (ischaemic),CeV,Cerebrovascular,Local injection,Bone marrow,Stem,Allogeneic,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
74,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657707/,Tsai,Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I/IIa Clinical Study,CELL TRANSPLANTATION,2017,Taiwan,Asia,I/IIa,I,Paracrine,n,n/a (not claimed),Spinocerebellar ataxia,CNS,Nervous system,Intravenous,Adipose,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,"Performed, no value reported","Performed, no value reported","Performed, no value reported","Performed, no value reported",OAC described as multipotency test,"Claimed (OAC, other)",Yes,9,0,9,greater than,90,release,p,minimum,95,release,p,minimum,95,release,p,minimum,95,release,p,maximum,2,release,p,maximum,2,release,p,maximum,2,release,p,NA,NA,NA,n,NA,NA,NA,n,maximum,2,release,p,maximum,2,release,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
75,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722100/,Tzouvelekis,"A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis",Journal of Translational Medicine,2013,Greece,Europe,I,I,Not stated,n,n/a (not claimed),Idiopathic pulmonary fibrosis,Resp,Respiratory,Intravenous,Adipose,Stromal,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,7,2,9,NA,NA,NA,n,average,67.7,measure,p,average,59.3,measure,p,average,50.1,measure,p,average,28.8,measure,p,NA,X,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,54.2,p,NA,X,m,NA,NA,NA,n,NA,NA,NA,n,NA,79.1,NA,p,average,90.3,measure,p,NA,n,NA,n,NA,n,NA,n,NA,n,CD116
76,https://www.celltherapyjournal.org/article/S1465-3249(16)30377-2/fulltext,Vaquero,An approach to personalized cell therapy in chronic complete paraplegia: The Puerta de hierro phase I/II clinical trial,CYTOTHERAPY,2016,Spain,Europe,I/IIa,I,Paracrine,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,9,0,9,greater than,95,release,p,greater than,90,release,p,greater than,90,release,p,greater than,90,release,p,less than,5,release,p,less than,5,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,less than,5,release,p,NA,NA,n,NA,n,NA,5,p,NA,NA,NA,n,greater than,90,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,"HLA-I, CD80 negative"
77,https://www.celltherapyjournal.org/article/S1465-3249(16)30618-1/fulltext,Vaquero,Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury,CYTOTHERAPY,2017,Spain,Europe,II,II,Paracrine,n,n/a (not claimed),Spinal cord injury,CNS,Nervous system,Intrathecal,Bone marrow,Stromal,Autologous,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,9,0,9,greater than,95,release,p,greater than,90,release,p,greater than,90,release,p,greater than,90,release,p,less than,5,release,p,less than,5,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,less than,5,release,p,NA,NA,n,NA,n,NA,5,p,NA,NA,NA,n,greater than,90,release,p,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,"HLA-I, CD80 negative"
78,https://www.sciencedirect.com/science/article/pii/S0006899313010809?via%3Dihub,Wang S,Umbilical cord mesenchymal stem cell transplantaion significantly improves neurological function in patients with sequelae of traumatic brain injury,BRAIN RESEARCH,2013,China,Asia,II,II,Multiple,n,n/a (not claimed),Traumatic brain injury,CNS,Nervous system,Intrathecal,Umbilical cord,Stem,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,8,0,8,NA,NA,NA,n,greater than,95,measure,p,greater than,95,measure,p,greater than,95,measure,p,maximum,5,measure,p,maximum,5,measure,p,maximum,5,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,less than,5,measure,p,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,greater than,95,measure,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
79,https://www.sciencedirect.com/science/article/pii/S1465324914008007,Wang X,Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors,CYTOTHERAPY,2015,China,Asia,II,II,Multiple,n,n/a (not claimed),Cerebral palsy,CNS,Nervous system,Intrathecal,Umbilical cord,Stromal,Allogeneic,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,9,0,9,greater than,93,release,p,NA,100,measure,p,NA,100,measure,p,NA,99.95,measure,p,NA,0.74,measure,p,NA,0.35,measure,p,NA,0.06,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,0.14,measure,p,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,99.82,measure,p,NA,n,NA,n,NA,n,NA,n,NA,n,NA
80,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694112/,Weiss,"A Placebo-Controlled, Randomized Trial of Mesenchymal Stem Cells in COPD",CHEST,2013,USA,North America,II,II,Paracrine,n,n/a (not claimed),Chronic obstructive pulmonary disease,Resp,Respiratory,Intravenous,Bone marrow,Stem,Allogeneic,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,"Performed, no value reported",Stated potency test performed - no information provided,Claimed (other),No,0,1,1,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
81,http://www.bmrat.org/index.php/BMRAT/article/view/11,Bui,Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study,Biomedical Research and Therapy,2014,Vietnam,Asia,II,II,Paracrine,n,n/a (not claimed),Osteoarthritis,MS,Musculoskeletal,Intraarticular,Adipose,Stem,Autologous,Not stated,Not stated,3. Tests done but % not reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,1,1,NA,d,NA,m,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
82,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762261/,Hare,Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy: The POSEIDON Randomized Trial,JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION,2012,USA,North America,I/IIa,I,Multiple,n,n/a (not claimed),Ischaemic cardiomyopathy,CVS,Cardiovascular,Intracardiac,Bone marrow,Stem,Both,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
83,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291766/,Hare,Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy POSEIDON-DCM Trial,JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,2017,USA,North America,I/IIa,I,Not stated,n,n/a (not claimed),Non-ischemic cardiomyopathy,CVS,Cardiovascular,Intracardiac,Bone marrow,Stem,Both,Not stated,Not stated,2. Average % reported,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,1,0,1,minimum,80,measure,p,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
84,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4111133/,Heldman,Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy: The TAC-HFT Randomized Trial,J American College of Cardiology,2014,USA,North America,IIb,II,Not stated,n,n/a (not claimed),Ischaemic cardiomyopathy,CVS,Cardiovascular,Intracardiac,Bone marrow,Stem,Autologous,Not stated,Not stated,5. No characterisation discussed,Not mentioned,Not mentioned,Not mentioned,Not mentioned,Not mentioned,None mentioned,No,0,0,0,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,n,NA,n,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,NA,NA,n,NA,n,NA,n,NA,n,NA,n,NA,n,NA
